776
Views
5
CrossRef citations to date
0
Altmetric
Articles

Development and evaluation of nanoparticles based on mPEG-PLA for controlled delivery of vinpocetine: in vitro and in vivo studies

&
Pages 157-162 | Received 20 Nov 2015, Accepted 28 Dec 2015, Published online: 02 Feb 2016

References

  • Adair JH, Parette MP, Altinoglu EI, Kester M. 2010. Nanoparticulate alternatives for drug delivery. ACS Nano. 4:4967–4970.
  • Bönöczk P, Gulyás B, Adam-Vizi V, et al. 2000. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 53:245–254.
  • Chen C, Yu CH, Cheng YC, et al. 2006. Biodegradable nanoparticles of amphiphilic triblock copolymers based on poly(3-hydroxybutyrate) and poly(ethylene glycol) as drug carriers. Biomaterials. 27:4804–4814.
  • Chen GX, Kim HK, Kim ES, Yoon JS. 2006. Synthesis of high-molecular-weight poly (L-lactic acid) through the direct condensation polymeriza tion of L-lactic acid in bulk state. Eur Polym J. 42:468–472.
  • Chiu PJ, Tetzloff G, Ahn HS, Sybertz EJ. 1988. Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta. Am J Hypertens. 1:262–268.
  • Discher DE, Ahmed F. 2006. Polymersomes. Annu Rev Biomed Eng. 8:323–341.
  • Domínguez A, Fernandez A, González N, et al. 1997. Determination of critical micelle concentration of some surfactants by three techniques. J Chem Educ. 74:1227–1231.
  • Dong Y, Feng SS. 2004. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 25:2843–2849.
  • Elbary A, Foda N, El-Gazayerly O, Khatib ME. 2002. Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Anal Lett. 35:1041–1054.
  • Elsabahy M, Wooley KL. 2012. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 41:2545–2561.
  • Fabregat G, Casanovas J, Redondo E, et al. 2014. A rational design for the selective detection of dopamine using conducting polymers. Phys Chem Chem Phys. 16:7850–7861.
  • Garlotta DA. 2001. A literature review of poly(lactic acid). J Polym Environ. 9:63–84.
  • Hindmarch I, Fuchs HH, Erzigkei H. 1991. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 6:31–43.
  • Jain AK, Goyal AK, Gupta PN, et al. 2009. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J Control Release. 136:161–169.
  • Kataoka K, Harada A, Nagasaki Y. 2001. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 47:113–131.
  • Kievit FM, Zhang M. 2011. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater Weinheim. 23:H217–H247.
  • Lavasanifar A, Samuelm J, Kwon GS. 2002. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 54:169–190.
  • Layre A, Couvreur P, Chacun H, et al. 2006. Novel composite core-shell nanoparticles as busulfan carriers. J Control Release. 111:271–280.
  • Levy MY, Benita S. 1990. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm. 66:29–37.
  • Miskolczi P, Korma K, Polgár M, Vereczkey L. 1990. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur J Drug Metab Pharmacokinet. 15:1–5.
  • Nagarwal RC, Kant S, Singh PN, et al. 2009. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 136:2–13.
  • Nishiyama N, Kataoka K. 2006. Nanostructured devices based on block copolymer assemblies for drug delivery: designing structures for enhanced drug function. Polym Ther II. 193:67–101.
  • Polgár M, Vereczkey L, Nyáry I. 1985. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion. J Pharm Biomed. Anal 3:131–139.
  • Pudleiner P, Vereczkey L. 1993. Study on the absorption of vinpocetine and apovincaminic acid. Eur J Drug Metab Pharmacokinet. 18:317–321.
  • Qiu Y, Garren J, Sammara E, et al. 2003. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method. J Pharm Sci. 92:2317–2325.
  • Rancan F, Blume-Peytavi U, Vogt A. 2014. Utilization of biodegradable polymeric materials as delivery agents in dermatology. Clin Cosmet Investig Dermatol. 7:23–34.
  • Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, et al. 2014. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 15:517–535.
  • Shah NB, Vercellotti GM, White JG, et al. 2012. Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties. Mol Pharm. 9:2146–2155.
  • Subhan Z, Hindmarch L. 1985. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 28:567–571.
  • Szakács T, Veres Z, Vereczkey L. 2001. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Pol J Pharmacol. 53:623–628.
  • Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov Today. 10:1451–1458.
  • Walkey CD, Olsen JB, Guo H, et al. 2012. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc. 134:2139–2147.
  • Washington C. 1990. Drug release from microdisperse systems: a critical review. Int J Pharm. 58:1–12.
  • Xiong MH, Bao Y, Yang XZ, et al. 2014. Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev. 78:63–76.
  • Zhang X, Li Y, Chen X, et al. 2005. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate. Biomaterials. 26:2121–2128.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.